Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

Alonso-Padilla_J_PLoS_Negl_Trop_Dis_2020.pdf (443.31 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-04-23

Llicència de publicació

cc by (c) Alonso-Padilla et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/162636

Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/ 10.1371/journal.pntd.0008035

Resum

Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite the fact they are not 100% effective in patients with chronic disease [9–12], they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change.

Matèries

Malaltia de Chagas, Parasitologia mèdica

Matèries (anglès)

Chagas' disease, Medical parasitology

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

ALONSO PADILLA, Julio, et al. Target product profile for a test for the early assessment of
                treatment efficacy in Chagas disease patients: An expert
                consensus. PLoS Neglected Tropical Diseases . 2020. Vol. 14, num. 4, pags. e0008035. ISSN 1935-2735. [consulted: 6 of August of 2026]. Available at: https://hdl.handle.net/2445/162636

Exportar metadades

JSON - METS

Compartir registre